DUBLIN (BUSINESS WIRE) The "COVID-19 - Competitive Landscape, 2023" report has been added to ResearchAndMarkets.com's offering.This "COVID-19 Competitive landscape 2023" report provides comprehensive insights about 400+ companies and 500+ drugs in COVID-19 Competitive landscape. It covers the therapeutics assessme.
Chinese vaccine developer Shanghai Zerun Biotechnology and its parent company Walvax will receive extra funding to advance the early stage clinical trials of a Covid-19 shot against all variants of concern, including Omicron.
Global foundation CEPI will invest another US$8.15 million to support phase 1 and 2 trials of the shot as well as a vaccine for the original coronavirus strain.